Small molecule · Inhibitor of HMG-CoA reductase (HMGCR) · developed by Upjohn
Atorvastatin is a statin that competitively inhibits HMG-CoA reductase, the rate-limiting enzyme of cholesterol synthesis in the liver. It also increases hepatic LDL receptor numbers, enhancing LDL uptake and clearance. It is studied in atherosclerotic cardiovascular disease, hypercholesterolemia, dyslipidemias, rheumatoid arthritis, and nonalcoholic steatohepatitis.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Apr 15, 2024). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03611010 | Phase 2 | Hypercholesterolemia | Completed | CPIX |
| NCT07534592 | Phase 1 | Healthy Participants | Active not recruiting | AZN |
| NCT06191991 | Phase 1 | Healthy Volunteers | Completed | ALGS |
| NCT04972396 | Phase 1 | NASH - Nonalcoholic Steatohepatitis | Completed | ALT |
| NCT04608344 | Phase 1 | Rheumatoid Arthritis | Completed | LKFT |
| NCT03760848 | Phase 1 | Healthy | Completed | EOCN |
| NCT03801733 | Phase 1 | Drug Interaction Potentiation | Completed | AKBA |
| NCT02749578 | Phase 1 | Healthy | Completed | MDGL |
| NCT06858332 | N/A | Atherosclerotic Cardiovascular Disease | Recruiting | NVS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Atherosclerotic Cardiovascular DiseaseHealthy ParticipantsDrug Interaction PotentiationDyslipidemiasHealthyHealthy VolunteersHypercholesterolemiaNASH - Nonalcoholic SteatohepatitisRheumatoid Arthritis
Updated Nov 15, 2026.